Our 161-page report provides 77 tables, 75 charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing CMO of sterile injectable drugs market. See how to exploit the opportunities.
Forecasts to 2030 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2030, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), Porter’s Five Forces Analysis, product profiles and commercial developments.
Discover sales predictions for the global market and submarkets
Along with revenue prediction for the overall world market, there are 4 segmentations of the CMO of sterile injectable drugs market, with forecasts for 5 product types, 6 applications, 2 molecules, 5 containers each forecasted at a global and regional level.
Global CMO of Sterile Injectable Drugs Market by Product Type
• Monoclonal antibodies
• Insulin
• Cytokines
• Vaccines
• Blood factors
• Others
Global CMO of Sterile Injectable Drugs Market by Application
• Cancer
• Diabetes
• Cardiovascular diseases
• CNS
• Infectious
• Others
Global CMO of Sterile Injectable Drugs Market by Molecule
• Large Molecule
• Small Molecule
Global CMO of Sterile Injectable Drugs Market by Container
• Bottles
• Ampoules
• Vials
• Prefilled syringes
• Bags
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 18 leading national markets:
• North America:
• US
• Canada
• Europe:
• Germany
• France
• UK
• Italy
• Spain
• Rest of Europe
• Asia-Pacific:
• Japan
• China
• India
• Rest of Asia-Pacific
• Latin America
• Middle East & Africa
Leading Companies covered in the report include:
• Jubilant Life Sciences Limited
• Boehringer Ingelheim
• Pfizer CentreOne
• Baxter Biopharma Solutions
• Recipharm AB
• Lonza
• Famar Health Care Services
• Patheon, Inc (Parent organization: Thermo Fischer company)
• Catalent, Inc
• Almac Group
• Evonik Industries AG
• Siegfried Holding AG
• Consort Medical, Plc.
• Aenova Group
• Grifols SA
The report also includes profiles and for some of the leading companies in the CMO of sterile injectable drugs market, with a focus on this segment of these companies’ operations:
• Famar Health Care Services
• Boehringer Ingelheim
• Baxter Biopharma Solutions
• Lonza
• Jubilant Life Sciences Limited
There will be growth in both established and in developing countries. Our analyses show that the both developed and developing markets, U.S., UK, Germany, Japan, India and China in particular, will continue to achieve high revenue growth to 2030.
Leading companies and the potential for market growth
Overall world revenue for CMO of sterile injectable drugs will surpass US$55.33 billion by 2030, our work calculates. We predict strong revenue growth through to 2030. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the CMO of Sterile Injectable Drugs Market report helps you
In summary, our 160 pages report provides you with the following knowledge:
• Revenue forecasts to 2030 for 4 segmentations of the CMO of Sterile Injectable Drugs market, with forecasts for 5 product types, 6 applications, 2 molecules, 5 containers, each forecasted at a global and regional level–discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2030 for 5 regional and 11 key national markets – See forecasts for the CMO of Sterile Injectable Drugs market in North America, Latin America, Europe, Asia-Pacific and Middle East & Africa. Also forecasted is the market in the US, Canada, Germany, France, UK, Italy, Spain, China, India, and Japan.
• Drivers, Restraints, Challenges, Opportunities
• Porter’s Five Forces Analysis
• Prospects for established firms and those seeking to enter the market– including company profiles for 15 of the major companies involved in the CMO of sterile injectable drugs market
• Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain study is for everybody needing commercial analyses for the CMO of Sterile Injectable Drugs market and leading companies. You will find data, trends and predictions.
Get our report today (CMO) of Sterile Injectable Drugs Market : Forecasts by Product Type (Monoclonal Antibodies, Insulin, Cytokines, Vaccines, Blood Factors, Others), Application (Cancer, Diabetes, Cardiovascular Diseases, CNS, Infectious, Others), Molecule (Small Molecule and Large Molecule), Container (Bottles, Ampoules, Vials, Bags, Pre-filled Syringes, Others) Plus Company Profiling of Major Players.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1 Global CMO of Sterile Injectable Drugs Market 2020-2030
1.1 Executive Summary
1.2 Why You Should Read This Report
1.3 What This Report Delivers
1.4 Key Questions Answered by This Analytical Report Include:
1.5 Who is This Report For?
1.6 Methodology
1.7 Frequently Asked Questions (FAQs)
1.8 Associated Visiongain Reports
1.9 About Visiongain
2 Introduction to the CMO of Sterile Injectable Drugs Market
2.1 Opportunities for the CMO of Sterile Injectable
2.2 CMO of Sterile Injectable Definition
2.3 CMO of Sterile Injectable Overview
2.3.1 Executive Summary
2.3.1 CMO of Sterile Injectable Segmentation
2.3.2 CMO of Sterile Injectable, By Large Molecule
2.3.3 CMO of Sterile Injectable, By Molecule Type
2.3.4 CMO of Sterile Injectable, By Container Type
3 Market Overview
3.1 Market Drivers
3.1.1 Increasing Prevalence of Chronic Diseases
3.1.2 Lucrative demand for biologics
3.1.3 Patent Cliff Till 2022
3.2 Market Restraints
3.2.1 Stringent Regulatory Requirements
3.3 Market Opportunities
3.3.1 Emerging Business Segments and Economies
3.4 Porter’s five forces
3.4.1 Bargaining Power of Buyers (High)
3.4.2 Bargaining Power of Suppliers (Low)
3.4.3 Threat of Substitutes (Low)
3.4.4 Threat of New Entrants (Medium)
3.4.5 Industry Rivalry (High)
4 Global CMO of Sterile Injectable Drugs Market by Molecule Type
4.1 Small Molecule Submarket Forecast 2020-2030
4.2 Large Molecule Submarket Forecast 2020-2030
5 Global CMO of Sterile Injectable Drugs Market by Large Molecule
5.1 Monoclonal antibodies Submarket Forecast 2020-2030
5.2 Insulin Submarket Forecast 2020-2030
5.3 Cytokines Submarket Forecast 2020-2030
5.4 Vaccines Submarket Forecast 2020-2030
5.5 Blood factors Submarket Forecast 2020-2030
5.6 Others Submarket Forecast 2020-2030
6 Global CMO of Sterile Injectable Drugs Market by Application
6.1 Cancer Submarket Forecast 2020-2030
6.2 Diabetes Submarket Forecast 2020-2030
6.3 Cardiovascular diseases Submarket Forecast 2020-2030
6.4 CNS Submarket Forecast 2020-2030
6.5 Infectious Submarket Forecast 2020-2030
6.6 Others Submarket Forecast 2020-2030
7 Global CMO of Sterile Injectable Drugs Market by Container
7.1 Bottles Submarket Forecast 2020-2030
7.2 Ampoules Submarket Forecast 2020-2030
7.3 Vials Submarket Forecast 2020-2030
7.4 Prefilled Syringe Submarket Forecast 2020-2030
7.5 Bags Submarket Forecast 2020-2030
8 Regional and Leading National CMO of Sterile Injectable Forecasts 2020-2030
8.1 Global CMO of Sterile Injectable by National Market Share Forecast 2020-2030
8.2 North America CMO of Sterile Injectable Forecast 2020-2030
8.2.1 U.S. CMO of Sterile Injectable Forecast 2020-2030
8.2.2 Canada CMO of Sterile Injectable Forecast 2020-2030
8.3 Europe CMO of Sterile Injectable Forecast 2020-2030
8.3.1 Germany CMO of Sterile Injectable Forecast 2020-2030
8.3.2 France CMO of sterile injectable Forecast 2020-2030
8.3.3 UK CMO of sterile injectable Forecast 2020-2030
8.3.4 Italy CMO of Sterile Injectable Forecast 2020-2030
8.3.5 Spain CMO of sterile injectable Forecast 2020-2030
8.3.6 Rest of Europe CMO of sterile injectable Forecast 2020-2030
8.4 Asia Pacific CMO of sterile injectable Forecast 2020-2030
8.4.1 China CMO of sterile Injectable Forecast 2020-2030
8.4.2 Japan CMO of Sterile Injectable Forecast 2020-2030
8.4.3 India CMO of sterile injectable Forecast 2020-2030
8.4.4 Rest of APAC CMO of sterile injectable Forecast 2020-2030
8.5 Latin America CMO of sterile injectable Forecast 2020-2030
8.6 Middle East & Africa CMO of sterile injectable Forecast 2020-2030
9 Leading Companies in the CMO of sterile injectable
9.1 Jubilant Life Sciences Limited
9.1.1 Jubilant Life Sciences Limited Total Company Sales 2016 - 2019
9.1.2 Jubilant Life Sciences Limited Products / Services
9.1.3 Jubilant Life Sciences Limited Mergers & Acquisitions (M&A) Activity
9.1.4 Jubilant Life Sciences Limited CMO outlook
9.2 Boehringer Ingelheim
9.2.1 Boehringer Ingelheim Total Company Sales 2016 - 2018
9.2.2 Boehringer Ingelheim Products / Services
9.2.3 Boehringer Ingelheim Mergers & Acquisitions (M&A) Activity
9.2.4 Boehringer Ingelheim CMO outlook
9.3 Recipharm AB
9.3.1 Recipharm AB Total Company Sales 2016 - 2018
9.3.2 Recipharm AB Products / Services
9.3.3 Recipharm AB Mergers & Acquisitions (M&A) Activity
9.3.4 Recipharm AB CMO outlook
9.4 Lonza
9.4.1 Lonza Total Company Sales 2016 - 2019
9.4.2 Lonza Products / Services
9.4.3 Lonza Mergers & Acquisitions (M&A) Activity
9.4.4 Lonza CMO outlook
9.5 Patheon, Inc (Parent organization: Thermo Fischer company)
9.5.1 Patheon, Inc Total Company Sales 2016 - 2019
9.5.2 Patheon, Inc Products / Services
9.5.3 Patheon, Inc Mergers & Acquisitions (M&A) Activity
9.5.4 Patheon, Inc CMO outlook
9.6 Catalent, Inc
9.6.1 Catalent, Inc Total Company Sales 2016 - 2019
9.6.2 Catalent, Inc. Products / Services
9.6.3 Catalent, Inc. Mergers & Acquisitions (M&A) Activity
9.6.4 Catalent, Inc. CMO outlook
9.7 Almac Group
9.7.1 Almac Group Total Company Sales 2018
9.7.2 Almac Group Products / Services
9.7.3 Almac Group Mergers & Acquisitions (M&A) Activity
9.7.4 Almac Group CMO outlook
9.8 Siegfried Holding AG
9.8.1 Siegfried Holding AG Total Company Sales 2016 - 2019
9.8.2 Siegfried Holding AG Products / Services
9.8.3 Siegfried Holding AG Mergers & Acquisitions (M&A) Activity
9.8.4 Siegfried Holding AG CMO outlook
9.9 Consort Medical, Plc.
9.9.1 Consort Medical, Plc. Total Company Sales 2016 - 2018
9.9.2 Consort Medical, Plc. Products / Services
9.9.3 Consort Medical, Plc. Mergers & Acquisitions (M&A) Activity
9.9.4 Consort Medical, Plc.CMO outlook
9.10 Aenova Group
9.10.1 Aenova Group Products / Services
9.11 Grifols SA
9.11.1 Grifols SA Total Company Sales 2016 - 2019
9.11.2 Grifols SA Products / Services
9.11.3 Grifols SA Mergers & Acquisitions (M&A) Activity
9.12 Famar Health Care Services
9.12.1 Famar Health Care Services Products / Services
9.12.2 Famar Health Care Services Mergers & Acquisitions (M&A) Activity
9.13 Evonik Industries AG
9.13.1 Evonik Industries AG Total Company Sales 2016 - 2019
9.13.2 Evonik Industries AG Products / Services
9.13.3 Evonik Industries AG Mergers & Acquisitions (M&A) Activity
9.14 Baxter Biopharma Solutions
9.14.1 Baxter Biopharma Solutions Total Company Sales 2016 - 2019
9.14.2 Baxter Biopharma Solutions Products / Services
9.14.3 Baxter Biopharma Mergers & Acquisitions (M&A) Activity
9.15 Pfizer CentreOne
9.15.1 Pfizer CentreOne Total Company Sales 2016 - 2019
9.15.2 Pfizer CentreOne Products / Services
9.15.3 Pfizer CentreOne Mergers & Acquisitions (M&A) Activity
10 Conclusions and Recommendations
10.1 Associated Visiongain Reports
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
List of Tables
Table 1. Executive Summary
Table 2. CVD Total Costs Through 2035
Table 3. HIV Vaccines, Passive Immunization, and Antibody Gene Transfer Pipeline
Table 4. List of Biologics and Growth Rate (%)
Table 5. Drugs Going Generic in 2020-2024
Table 6. CDMO PE Buyouts
Table 7. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Molecule Type (US$ million, AGR %)
Table 8. Small Molecule Revenue Forecast 2020-2030 (US$ million, AGR %)
Table 9. Large Molecule Revenue Forecast 2020-2030 (US$ million, AGR %)
Table 10. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030, Large Molecule (US$ million, AGR %)
Table 11. Global Monoclonal Antibodies Revenue Forecast 2020-2030 (US$ million, AGR %)
Table 12. Insulin Revenue Forecast 2020-2030 (US$ million, AGR %)
Table 13. Global Cytokines Revenue Forecast 2020-2030 (US$ million, AGR %)
Table 14. Global Vaccines Revenue Forecast 2020-2030 (US$ million, AGR %)
Table 15. Global Blood factors Revenue Forecast 2020-2030 (US$ million, AGR %)
Table 16. Global Others Sub Market Revenue Forecast 2020-2030 (US$ million, AGR %)
Table 17. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Application (US$ million, AGR %)
Table 18. U.S. Perspective on the Highest-Selling Drugs in 2018
Table 19. Cancer Revenue Forecast 2020-2030 (US$ million, AGR %)
Table 20. Diabetes Revenue Forecast 2020-2030 (US$ million, AGR %)
Table 21. Cardiovascular diseases Revenue Forecast 2020-2030 (US$ million, AGR %)
Table 22. CNS Revenue Forecast 2020-2030 (US$ million, AGR %)
Table 23. Infectious Revenue Forecast 2020-2030 (US$ million, AGR %)
Table 24. Others Revenue Forecast 2020-2030 (US$ million, AGR %)
Table 25. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Container (US$ million, AGR %)
Table 26. Bottles Revenue Forecast 2020-2030 (US$ million, AGR %)
Table 27. Ampoules Revenue Forecast 2020-2030 (US$ million, AGR %)
Table 28. Vials Revenue Forecast 2020-2030 (US$ million, AGR %)
Table 29. Prefilled Syringe Revenue Forecast 2020-2030 (US$ million, AGR %)
Table 30. Bags Revenue Forecast 2020-2030 (US$ million, AGR %)
Table 31. The North American CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Large Molecule (US$ million, AGR %)
Table 32. The North America CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Application (US$ million, AGR %)
Table 33. The North American CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Molecule (US$ million, AGR %)
Table 34. The North American CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Container (US$ million, AGR %)
Table 35. U.S. CMO of Sterile Injectable Forecast 2020-2030 (US$ million, AGR %)
Table 36. Canada CMO of Sterile Injectable Forecast 2020-2030 (US$ million, AGR %)
Table 37. Europe CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Large Molecule (US$ million, AGR %)
Table 38. Europe CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Application (US$ million, AGR %)
Table 39. Europe CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Molecule (US$ million, AGR %)
Table 40. Europe CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030, by Container (US$ million, AGR %)
Table 41. Germany CMO of sterile injectable Forecast (US$ million, AGR %)
Table 42. France CMO of sterile injectable Forecast (US$ million, AGR %)
Table 43. UK CMO of sterile injectable Forecast (US$ million, AGR %)
Table 44. Italy CMO of sterile injectable Forecast (US$ million, AGR %)
Table 45. Spain CMO of sterile injectable Forecast (US$ million, AGR %)
Table 46. Rest of Europe CMO of sterile injectable Forecast (US$ million, AGR %)
Table 47. Asia Pacific CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Large Molecule (US$ million, AGR %)
Table 48. Asia Pacific CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Application (US$ million, AGR %)
Table 49. Asia Pacific CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Molecule (US$ million, AGR %)
Table 50. Asia Pacific CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Container (US$ million, AGR %)
Table 51. China CMO of Sterile Injectable Forecast (US$ million, AGR %)
Table 52. Japan CMO of sterile injectable Forecast (US$ million, AGR %)
Table 53. India CMO of sterile injectable Forecast (US$ million, AGR %)
Table 54. Rest of APAC CMO of sterile injectable Forecast (US$ million, AGR %)
Table 55. Latin America CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Large Molecule (US$ million, AGR %)
Table 56. Latin America CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Application (US$ million, AGR %)
Table 57. Latin America CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Molecule (US$ million, AGR %)
Table 58. Latin America CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Container (US$ million, AGR %)
Table 59. Middle East & Africa CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Large Molecule (US$ million, AGR %)
Table 60. Middle East & Africa CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Application (US$ million, AGR %)
Table 61. Middle East & Africa CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Molecule (US$ million, AGR %)
Table 62. Middle East & Africa CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Container (US$ million, AGR %)
Table 63. Jubilant Life Sciences Limited Company Overview
Table 64. Boehringer Ingelheim company overview
Table 65. Recipharm AB company overview
Table 66. Lonza company overview
Table 67. Patheon, Inc. company overview ( Thermo Fischer company)
Table 68. Catalent, Inc. company overview
Table 69. Almac Group company overview
Table 70. Almac Group Total Company Sales 2018
Table 71. Siegfried Holding AG company overview
Table 72. Consort Medical, Plc. Company overview
Table 73. Jubilant Life Sciences Limited company overview
Table 74. Grifols SA company overview
Table 75. Famar Health Care Services company overview
Table 76. Famar Health Care Services Total Company Sales 2017
Table 77. Evonik Industries AG company overview
Table 78. Baxter Biopharma Solutions company overview
Table 79. Pfizer CentreOne company overview
List of Figures
Figure 1. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 (US$ million, AGR%)
Figure 2. Objectives and Relationship of Customer and CMO
Figure 3. CMO of Sterile Injectable Segmentation
Figure 4. CMO of sterile injectable DRO
Figure 5. Worldwide Sales at Risk from Patent Expiration (2019-2024)
Figure 6. Top 10 Therapy Areas in 2024, Market Share & Sales Growth
Figure 7. Survey of U.S. Based Companies: Destination for International Outsourcing “Strong Likelihood” or “Likelihood” for the Next 5 Years
Figure 1. CMO of Sterile Injectable Drugs Market Porter’s Five Forces
Figure 2. CMO of Sterile Injectable Drugs Market by Molecule Type
Figure 3. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Application (US$ million)
Figure 4. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Application (%)
Figure 5. Small Molecule Revenue Forecast 2020-2030 (US$ million, AGR %)
Figure 6. Large Molecule Revenue Forecast 2020-2030 (US$ million, AGR %)
Figure 7. CMO of Sterile Injectable Drugs Market by Large Molecule
Figure 8. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Large Molecules (US$ million)
Figure 9. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Large Molecule (%)
Figure 10. Global Monoclonal antibodies Revenue Forecast 2020-2030 (US$ million, AGR %)
Figure 11. Insulin Revenue Forecast 2020-2030 (US$ million, AGR %)
Figure 12. Global Cytokines Revenue Forecast 2020-2030 (US$ million, AGR %)
Figure 13. Global Vaccines Revenue Forecast 2020-2030 (US$ million, AGR %)
Figure 14. Global Blood Factors Revenue Forecast 2020-2030 (US$ million, AGR %)
Figure 15. Global Blood Factors Revenue Forecast 2020-2030 (US$ million, AGR %)
Figure 16. CMO of Sterile Injectable Drugs Market by Application
Figure 17. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Application (US$ million)
Figure 18. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Application (%)
Figure 19. Cancer Revenue Forecast 2020-2030 (US$ million, AGR %)
Figure 20. Diabetes Revenue Forecast 2020-2030 (US$ million, AGR %)
Figure 21. Cardiovascular diseases Revenue Forecast 2020-2030 (US$ million, AGR %)
Figure 22. CNS Revenue Forecast 2020-2030 (US$ million, AGR %)
Figure 23. Infectious Revenue Forecast 2020-2030 (US$ million, AGR %)
Figure 24. Others Revenue Forecast 2020-2030 (US$ million, AGR %)
Figure 25. CMO of Sterile Injectable Drugs Market by Container
Figure 26. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Container (US$ million)
Figure 27. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Containers (%)
Figure 28. Bottles Revenue Forecast 2020-2030 (US$ million, AGR %)
Figure 29. Ampoules Revenue Forecast 2020-2030 (US$ million, AGR %)
Figure 30. Vials Revenue Forecast 2020-2030 (US$ million, AGR %)
Figure 31. Prefilled Syringe Revenue Forecast 2020-2030 (US$ million, AGR %)
Figure 32. Bags Revenue Forecast 2020-2030 (US$ million, AGR %)
Figure 8. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Containers (%)
Figure 9. The North America CMO of Sterile Injectable Forecast 2020-2030 (US$ million, AGR %)
Figure 10. U.S. CMO of Sterile Injectable Forecast 2020-2030 (US$ million, AGR %)
Figure 11. Canada CMO of sterile injectable Forecast 2020-2030 (US$ million, AGR %)
Figure 12. Europe CMO of Sterile Injectable Forecast 2020-2030 (US$ million, AGR %)
Figure 13. Germany CMO of sterile injectable Forecast (US$ million, AGR %)
Figure 14. France CMO of sterile injectable Forecast (US$ million, AGR %)
Figure 15. UK CMO of sterile injectable Forecast (US$ million, AGR %)
Figure 16. Italy CMO of sterile injectable Forecast (US$ million, AGR %)
Figure 17. Spain CMO of sterile injectable Forecast (US$ million, AGR %)
Figure 18. Rest of Europe CMO of sterile injectable Forecast (US$ million, AGR %)
Figure 19. Asia Pacific CMO of sterile injectable Forecast 2020-2030 (US$ million, AGR %)
Figure 20. China CMO of Sterile Injectable Forecast (US$ million, AGR %)
Figure 21. Japan CMO of sterile injectable Forecast (US$ million, AGR %)
Figure 22. India CMO of sterile injectable Forecast (US$ million, AGR %)
Figure 23. Rest of APAC CMO of sterile injectable Forecast (US$ million, AGR %)
Figure 24. Latin America CMO of Sterile Injectable Forecast 2020-2030 (US$ million, AGR %)
Figure 25. Middle East & Africa CMO of sterile injectable Forecast 2020-2030 (US$ million, AGR %)
Figure 26. Jubilant Life Sciences Limited Total Company Sales 2016-2019
Figure 27. Total Company Sales by business segment, 2019
Figure 28. Products / Services
Figure 29. Mergers & Acquisitions (M&A) Activity
Figure 30. Boehringer Ingelheim Total Company Sales 2016-2018
Figure 31. Total Company Sales by business segment, 2019
Figure 32. Products / Services
Figure 33. Mergers & Acquisitions (M&A) Activity
Figure 34. Recipharm AB Total Company Sales 2016-2018
Figure 35. Total Company Sales by business segment, 2018
Figure 36. Products / Services
Figure 37. Mergers & Acquisitions (M&A) Activity
Figure 38. Lonza Total Company Sales 2016-2019
Figure 39. Total Company Sales by business segment, 2019
Figure 40. Products / Services
Figure 41. Mergers & Acquisitions (M&A) Activity
Figure 42. Patheon, Inc. Total Company Sales 2016-2019
Figure 43. Total Company Sales by business segment, 2019
Figure 44. Products / Services
Figure 45. Mergers & Acquisitions (M&A) Activity
Figure 46. Catalent, Inc. Total Company Sales 2016-2019
Figure 47. Total Company Sales by business segment, 2019
Figure 48. Products / Services
Figure 49. Mergers & Acquisitions (M&A) Activity
Figure 50. Products / Services
Figure 51. Mergers & Acquisitions (M&A) Activity
Figure 52. Siegfried Holding AG Total Company Sales 2016-2019
Figure 53. Products / Services
Figure 54. Mergers & Acquisitions (M&A) Activity
Figure 55. Consort Medical, Plc. Total Company Sales 2016-2018
Figure 56. Total Company Sales by business segment, 2018
Figure 57. Products / Services
Figure 58. Mergers & Acquisitions (M&A) Activity
Figure 59. Products / Services
Figure 60. Grifols SA Total Company Sales 2016-2019
Figure 61. Total Company Sales by business segment, 2019
Figure 62. Products / Services
Figure 63. Mergers & Acquisitions (M&A) Activity
Figure 64. Products / Services
Figure 65. Mergers & Acquisitions (M&A) Activity
Figure 66. Evonik Industries AG Total Company Sales 2016-2019
Figure 67. Total Company Sales by business segment, 2019
Figure 68. Products / Services
Figure 69. Mergers & Acquisitions (M&A) Activity
Figure 70. Baxter Biopharma Solutions Total Company Sales 2016-2019
Figure 71. Total Company Sales by business segment, 2019
Figure 72. Products / Services
Figure 73. Mergers & Acquisitions (M&A) Activity
Figure 74. Pfizer CentreOne Total Company Sales 2016-2019
Figure 75. Total Company Sales by business segment, 2019
Figure 76. Products / Services
Figure 77. Mergers & Acquisitions (M&A) Activity
Figure 78. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 (US$ million, AGR %)
Figure 79. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Large Molecule (US$ million)
Figure 80. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Large Molecule (%)
Figure 81. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Application (US$ million)
Figure 82. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Application (%)
Figure 83. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Molecule (US$ million)
Figure 84. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Molecule (%)
Figure 85. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Container (US$ million)
Figure 86. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Containers (%)
Aenova Group
Baxter Biopharma Solutions
Boehringer Ingelheim
Catalent, Inc
Consort Medical, Plc.
Evonik Industries AG
Famar Health Care Services
Grifols SA
Jubilant Life Sciences Limited
Lonza
Patheon, Inc (Parent organization: Thermo Fischer company)
Pfizer CentreOne
Recipharm AB
Siegfried Holding AG
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
